SHIFT 45+
Core & Pro
A two-tier women's wellness gummy line — built for the US + EU peri-menopausal market. Core for the everyday funnel. Pro for the clinical-grade upgrade.
Internal Strategy Document · 2026Contents
Chapter IExecutive Summary
A nineteen-ingredient women's wellness gummy line, designed for the woman aged forty-five and above who refuses to choose between metabolic health, menopausal relief, and clinical credibility.
SHIFT 45+ launches as a two-tier product line:
- SHIFT 45+ Core — 2 gummies daily at $69 retail. The mass-funnel lead SKU. Lower friction, higher hook-rate in paid social, drives 75% of unit volume.
- SHIFT 45+ Pro — 3 gummies daily at $89 retail. The premium-tier upgrade, served on the product page as the "full clinical dose" option. Drives 25% of volume but 35% of LTV.
The line targets the world's fastest-growing women's health category. The global menopause supplement market reached USD 983 million in 2024 and is projected to grow to USD 24 billion by 2030. The category recently saw its first major exit — Pharmavite acquired Bonafide Health for USD 425 million in September 2024 — and Wile raised USD 111 million to enter Whole Foods nationwide.
Both variants share the same six globally-patented hero ingredients at identical clinical-trial doses: Berbevis® Berberine Phytosome, kudzu-sourced S-equol, Affron® Saffron, KSM-66 Ashwagandha, Cinnulin PF® Cinnamon, and MenaQ7® Vitamin K2. Pro adds the full PCOS-grade inositol dose (2g vs Core's 300mg) plus restored supporting actives. Manufactured by Chongqing Mengtai Biotechnology with vertical integration in Tongnan, China — one of the world's three premier lemon-growing regions.
First-year revenue target is USD 1.42 million blended ($1.1M Core + $320K Pro) at ~25,000 Core bottles and ~3,600 Pro bottles, scaling to USD 12 million by year three — aligned with the Bonafide acquisition-comp benchmark. The launch begins in the United States via direct-to-consumer and Amazon, expanding through the United Kingdom, Germany, Italy, France, and the Nordics in months five through eight.
Chapter IIMarket Opportunity
The menopause supplement category is experiencing a generational shift in cultural permission, consumer education, and capital deployment.
Category Size & Growth
| Metric | Value | Source / Year |
|---|---|---|
| Global menopause supplement market (2024) | $983 million | Future Market Insights |
| Projected total menopause market by 2030 | $24 billion | Industry research, 2025 |
| Compound annual growth rate (H1 2025-2035) | 5.6% | vs 5.3% the prior period |
| US share of global market | ~55% | Industry estimate |
| TikTok #menopausetok growth year-over-year | 540% | 2024-2025 cultural inflection |
Category-Defining Moments (Recent)
- September 2024 — Pharmavite acquires Bonafide Health for $425 million (exit-multiple comparable now set)
- September 2025 — Bonafide enters Target retail nationwide, marking the mass-channel inflection
- 2024 — Wile raises $111 million in venture funding, expanding into Whole Foods
- January 2023 — O Positiv launches MENO, the first menopause gummy in market
- June 2025 — Valerie's "Peri-Paradox" campaign wins NutraIngredients awards for boldest peri-menopause marketing
Menopause was a whispered category in 2019. It became a $425 million exit in 2024. By 2030, it will be a $24 billion industry. The product launched now lands in a market that is finally ready to talk back.
Chapter IIICompetitive Landscape
No incumbent owns the multi-mechanism category. Each leading brand stakes a single claim. SHIFT 45+ Max consolidates twelve.
| Brand | Position | Price (USD) | Active Count | SHIFT-45+ Advantage |
|---|---|---|---|---|
| Bonafide Thermella | Hot flash (curcumin-led) | $60 | 3 | 4× more actives at competitive price |
| Bonafide Relizen | Hot flash (pollen extract only) | $35-60 | 1 | Multi-mechanism vs single-symptom |
| Equelle (Pharmavite-Otsuka) | S-equol only, soy-source | $43-60 | 1 | Non-soy S-equol + 11 other actives |
| Goli ACV | Apple cider vinegar mass | $25 | 1 | 12× the active depth |
| Estroven Complete | Mass-market menopause | $25 | 4 | Full dose disclosure, no proprietary blends |
| Thorne Meta-Balance | Clinician-channel premium | $45-55 | ~6 | Patent-named heroes vs generic actives |
| Momentous Berberine | Single-active metabolic | $50 | 1 | Double the berberine dose at competitive price |
| Nutrafol Women | Hair-loss premium | $88 | ~6 | Different category — non-competing |
Positioning Verdict
The category is fragmented by symptom focus. Bonafide owns "hot flash". Goli owns "ACV". Equelle owns "S-equol". None own "the full perimenopause body shift in one bottle."
SHIFT 45+ Max claims the entire transition — weight management, hot flashes, sleep, mood, bone, and metabolic stability — at a price point that beats Bonafide by ten dollars while offering four times the active ingredients.
Chapter IVProduct Strategy
Three gummies per day — two with breakfast for metabolism, one with dinner for sleep. Each dose matches published clinical trial dosing.
Six Hero Ingredients (clinical-trial-dose-matched)
| Ingredient | Daily Dose | Clinical Evidence |
|---|---|---|
| Berbevis® Berberine Phytosome (Italy) | 1,100 mg | PCOS trial 2023: -5.2% body weight, 70% menstrual regularity restoration, -23.5% free testosterone in 90 days. 9.6× absorption vs standard berberine. |
| S-equol from Kudzu Root (non-soy) | 10 mg | Otsuka 2012 trial in 114 postmenopausal women: 58.7% hot flash reduction vs 34.5% placebo, p<0.01. Works for the 65-80% of Western women who are equol non-producers. |
| Inositol myo + d-chiro 40:1 | 2,000 mg | PCOS-grade insulin sensitizer. Restores HOMA-IR. Critical for peri-menopausal insulin resistance. |
| Affron® Saffron (Spain) | 28 mg | 2021 perimenopausal trial in 86 women: 33% nervousness reduction, 32% mood improvement at 12 weeks. No estrogenic effects. |
| KSM-66® Ashwagandha (India) | 100 mg | Cortisol modulation, sleep onset reduction, GABA-mimetic activity. Multiple RCTs for sleep + anxiety. |
| Alpha-Lipoic Acid (R-form) | 200 mg | Mitochondrial + insulin sensitizer. Three-pathway metabolic synergy with berberine and inositol. |
Supporting Cast (13 additional actives)
Apple cider vinegar powder, Cinnulin PF® cinnamon, Sunphenon® EGCG (decaf green tea), chromium picolinate, vitamin D3, MenaQ7® vitamin K2, magnesium glycinate, B6 in active P-5-P form, methylated folate, twelve-strain patented probiotic (pectin-coated for 98% intestinal survival), lemon-pectin prebiotic, natural edible lemon oil, and vitamin C from NFC Tongnan lemon juice.
Format & Flavor
Lemon-Ginger Vegan
Sicilian cold-pressed lemon oil meets gingerol-rich ginger extract, softened with Madagascar vanilla and monk fruit. A daily wellness shot made gentle.
Lemon-Blueberry
Wild blueberry meets Tongnan lemon — natural anthocyanin color paints each gummy deep purple-magenta. Antioxidant berry, beauty within.
Format: 3 high-load pectin gummies daily (90 gummies × 2g per bottle = 30-day supply).
Allergen panel:
Vegan
Soy-free
Gluten-free
Dairy-free
Honey-free
Non-GMO
Hormone-free
Melatonin-free
Chapter VCustomer Profiles
Four primary customer segments drive seventy percent of revenue. Each is reached through a distinct channel with a distinct message.
The Reader
Researches every ingredient on PubMed before purchase. Reads supplement-fact panels. Converts on citation density. Highest lifetime value, lowest acquisition cost.
"Twelve ingredients. Four clinical trials. Every dose disclosed."
The Loyalist
Family-pharmacy-loyal. ISTJ. Once trust is earned, subscribes for years. Top referral source — recommends to her women's group, her sisters, her doctor.
"What my gynecologist said about phytoestrogens — and what she didn't."
The Stress-Eater
Eighteen months into perimenopause. Stress-eats at 4pm. Has tried Ozempic for friends and wants a natural alternative. High viral velocity on Instagram and TikTok.
"I gained fifteen pounds in eighteen months without changing my diet. This is what worked."
The Stacker
Microdoses semaglutide off-label. Worried about hair shedding and muscle loss. Stacks supplements with prescription medication. Strong Reddit community presence.
"What I take with my Mounjaro — for the metabolic and hair side."
Secondary Customer Profiles (30% of revenue, EU expansion)
| Profile | Country | Channel | Hook |
|---|---|---|---|
| The Berlin Biohacker | Germany | Biohacker forums, Telegram | "Italian Berbevis® + kudzu S-equol — every dose disclosed" |
| The Paris Clean-Beauty | France | Instagram, Goop EU | "Hormone-free. Soy-free. Multi-mechanism." |
| The Roman Native | Italy | Family doctor, women's magazines | "Estromineral evolved — kudzu S-equol + full Berbevis® dose" |
| The Stockholm Hormone-Free | Sweden / Norway | Substack, Apple News, Spotify | "Non-hormonal — peer-reviewed evidence at every dose" |
Chapter VIAdjacent Markets
Five neighboring categories represent expansion opportunities in Year Two and beyond.
| Adjacent Category | Market Size | SHIFT-45+ Angle | Year-2 Opportunity |
|---|---|---|---|
| GLP-1 Alternative | ~6M US women off-label | "Stack with your GLP-1" — Stacker segment | 20-25% revenue capture |
| Longevity / Biohacker | $80M+ ARR category | Multi-active depth, female peri-specific | Line extension with NMN, Spermidine |
| Beauty-from-Within | $7.5B global | S-equol skin elasticity data | Variant with collagen + hyaluronic acid |
| Mental Wellness / Sleep | $42B + $20B | Evening gummy sleep-cue ritual | Lean further into sleep narrative |
| PCOS / Fertility | $1.4B and growing | Same myo+d-chiro 40:1 backbone | Variant for 28-40 cohort |
Chapter VIIPricing Strategy
Two tiers, two missions. Core wins the ad-funnel; Pro wins the lifetime value.
Tier Pricing by Region
| Region | SHIFT 45+ Core (2 gummies/day) | SHIFT 45+ Pro (3 gummies/day) | ||
|---|---|---|---|---|
| Retail | Subscribe | Retail | Subscribe | |
| United States | $69 | $55 | $89 | $71 |
| United Kingdom | £55 | £44 | £71 | £57 |
| European Union | €59 | €47 | €79 | €63 |
All subscribers receive 20% off retail with a 1-year price-lock. Subscribe-and-save at 20% (not 25%, not 15%) is the Goldilocks zone proven by extensive market research — higher discounts trigger desperation perception; lower discounts fail to move the 37% of trial-first customers.
Unit Economics per Variant
| Metric | Core | Pro |
|---|---|---|
| Landed COGS / bottle | $4.40 | $5.10 |
| Retail gross margin | 94% | 94% |
| Subscribe gross margin (post-discount) | 92% | 93% |
| Customer Acquisition Cost (CAC) | $32 | via PDP upgrade (zero incremental CAC) |
| 12-month LTV | $240 | $360 |
| LTV : CAC ratio | 7.5× | infinite (zero incremental CAC) |
Why Two Tiers vs One
Initial market research validated $79 retail as the demand-revenue optimum in pure purchase-intent testing. But when the full paid-acquisition funnel was modeled — hook-rate, click-through, add-to-cart, checkout completion, subscribe rate, and 60-day retention — a counter-intuitive finding emerged:
Core (2-gummy at $69) generates $512 of first-purchase revenue per 100 ad impressions. Pro (3-gummy at $79) generates $413. The two-gummy "just 2 a day" frame produces a 24% higher buyer rate at the checkout funnel — even though the same buyers, when asked, say they prefer the full clinical dose.
This is the classic intent–behavior gap. Customers say they want the full dose. They click the lower-friction option in paid social. The solution is to lead with Core in paid media and offer Pro as a product-page upgrade card for the customer who self-identifies as wanting clinical-grade dosing.
Customer-segment data confirms this split: 9 of 12 customer segments prefer Core when forced to choose. Three segments (the Reader, the Berlin Biohacker, the London Financial) prefer Pro — and these three segments represent the highest-LTV cohorts. The dual-tier strategy serves both without checkout-time SKU confusion.
Chapter VIIIFive Strategic Advantages
Each is an asymmetric bet that the incumbents cannot easily copy.
Kudzu-Sourced S-Equol
Otsuka-Pharmavite's Equelle® brand is locked into soy-derived S-equol. We source S-equol from kudzu root (Pueraria lobata) via Lactococcus 20-92 fermentation — the same molecule, with no soy in the supply chain. This bypasses the soy-allergen objection flagged by seventy percent of Western women in customer research, and positions us as the "post-soy" S-equol brand. Twelve-month supplier exclusivity makes this a first-mover lock.
Evening Gummy as Sleep Cue
Every other supplement instructs "take with breakfast". We reframe the split dose — two in the morning for metabolism, one in the evening for sleep — as a ritual cue rather than a pill burden. Customer research showed seven of twelve customer segments specifically called out the evening gummy as a benefit, not a chore. Habits anchored to dinner are stickier than morning-only habits. This drives the 93% subscribe-after-trial intent.
Double the Berbevis® Dose at Lower Per-Milligram Cost
Momentous sells Berbevis® Berberine Phytosome at 550 mg per day for $50. SHIFT 45+ Max delivers 1,100 mg — double the dose — plus eleven additional clinical-grade actives, at $79 retail. That is 21% lower per-milligram cost on the hero ingredient, plus an entire multi-mechanism stack. The math is visible to any customer who reads a supplement-fact panel.
Multi-Mechanism at Gummy Price Point
Bonafide Thermella retails at $60 for three active ingredients — twenty dollars per active. SHIFT 45+ Max delivers twelve actives at $79 retail — six dollars and fifty cents per active. Three times the value density per dollar. For the Reader segment, this calculation is the conversion event.
Dual-Tier Strategy — Core Wins Ads, Pro Wins LTV
Customer research revealed an intent–behavior gap. When asked "which would you buy?", 86% chose the 3-gummy full-clinical-dose option. But when full paid-acquisition funnel was modeled, the 2-gummy variant generated 24% more buyers per 100 ad impressions due to lower mental-commitment friction. The solution: lead all paid social with the Core 2-gummy variant at $69 (the high-throughput ad funnel), then surface the Pro 3-gummy variant on the product page as an upgrade card for the citation-density customer who self-identifies. This captures both segments without checkout SKU confusion. Expected Year-One contribution: Core $1.1M direct + Pro $320K incremental upgrade — a 29% revenue lift versus a single-SKU launch.
Chapter IXLaunch Plan
Production compressed to thirty days from RFQ to mass production. First DTC sale within Month One. Full European Union expansion deferred to Year Two — Year One is laser-focused on Meta-driven US scale.
Factory Timeline — 30 Days to Mass Production
Quote + sample batch
Sensory verification
Mass production run
Ship to US warehouse
Go-to-Market Timeline — Meta-Driven US Scale
US DTC launch · Meta-only
Meta creative-test cycle
Meta scale + creator UGC
Subscribe lock-in cycle
Trustpilot 500+ milestone
Year-end consolidation
Chapter XInvestment & Returns
Year One is a Meta-only focus play. Other channels open in Year Two only after the Meta funnel is proven and the Trustpilot base is established.
| Period | Revenue Target | Core Volume | Pro Volume | Gross Profit |
|---|---|---|---|---|
| Year 1 | $1.42M blended | ~16,000 bottles | ~3,600 bottles | $1.10M |
| Year 2 | $5.5 million | ~60,000 bottles | ~12,000 bottles | $4.13M |
| Year 3 | $12 million | ~130,000 bottles | ~30,000 bottles | $9.0M |
Channel Spend Allocation
One hundred percent of paid acquisition budget flows through Meta (Facebook + Instagram) in Year One. The decision is deliberate: a single-channel focus produces faster learning loops, simpler attribution math, and higher operator concentration. Other channels — Amazon, Reddit, TikTok Shop, Substack — open in Year Two only after the Meta funnel proves itself with positive unit economics at scale.
| Channel | Year 1 Allocation | Approx. USD | Year 2 Status |
|---|---|---|---|
| Meta (Facebook + Instagram) | 100% | $320,000 | Continue + scale |
| Amazon (DSP + organic) | — | — | Open in Year 2 after Meta proven |
| Reddit + Substack sponsorships | — | — | Year 2 expansion (Reader segment) |
| TikTok Shop + creators | — | — | Year 2 (after Trustpilot 500+) |
| Influencer + podcast partnerships | — | — | Year 2 (Loyalist + Reader) |
| Retail entry (Sprouts → Whole Foods) | — | — | Year 2-3 after NSF + USP cert |
Why Meta-Only in Year One
- Faster learning loop: single attribution surface, single creative-test queue, faster iteration on hooks + audiences
- Operator concentration: one person can run Meta well; running six channels well requires six people
- Proof of unit economics first: if Meta cannot generate LTV : CAC ≥ 5×, no amount of channel diversification fixes the underlying funnel
- Lower fixed-cost burn: no Amazon Vine fees, no influencer retainers, no Reddit sponsorship minimums — every dollar goes to ad spend or creative production
- Audience density: Meta still indexes the highest density of women aged 45-60 globally — 78% scroll daily, the highest of any platform tested
Key Performance Indicators (Year One — Meta-driven)
The Bonafide Health acquisition closed at $425 million in September 2024. The category multiple for menopause supplements is now publicly observable. Year-three revenue of $12 million places SHIFT 45+ squarely in the acquisition-comp window — a three-to-five-year strategic-buyer outcome with Pharmavite, Procter & Gamble, or Unilever as plausible acquirers.
Chapter XIRisks & Mitigations
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Kudzu S-equol supplier MOQ too high | Medium | High | Pre-commit 25kg with primary supplier; secondary supplier identified as backup |
| Manufacturer cannot ferment kudzu in-house | Medium | High | Source SE5-OH ingredient via Otsuka-licensed channel as Plan B |
| Berberine GI side effects at 1,100mg dose | Medium | Medium | Phytosome form reduces GI by 60%; first-week starter dose protocol on label |
| EU per-country supplement notification slow | High | Medium | Sequence US → UK → DE → IT to phase regulatory load over 8 months |
| Competitor copies the kudzu positioning in Year 2 | High | Low | First-mover advantage + 12-month exclusive supplier deal |
| FDA / FTC enforcement on "Nature's Ozempic" claims | Medium | High | Frame as "metabolic resilience" not weight-loss; structure-function compliant copy throughout |
| Trust concerns over Chinese manufacturing origin | Medium | Medium | Lead with Tongnan terroir narrative; NSF Certified for Sport® + USP Verified by Month 9 |
Chapter XIIOpen Decisions
The strategy is locked. The execution requires founder sign-off on these final ten items.
- Final formula confirmation at 3 gummies daily, kudzu S-equol, $79 retail and $63 subscribe
- Brand house structure — Sunside Sdn Bhd as parent, SHIFT 45+ Max as product line, or sub-brand creation
- Kudzu supplier selection — primary supplier in France (90-day lead time, cleanest EU regulatory path) versus secondary in China (45-day lead time, lower cost)
- Pilot batch size — 500 bottles (lowest risk) versus 2,000 bottles (cheaper per unit, larger cash commitment)
- Launch geography phasing — US only Months 1-3 then EU expansion, versus US + UK simultaneous launch
- Premium upgrade timing — launch Month 1 alongside Core, or Month 3 post-traction
- Brand visual identity — direction confirmation for label artwork (Tricia handoff)
- TikTok Shop timing — Month 3 (early) versus Month 5 (after Trustpilot baseline established)
- Year 2 line extension priority — Pro tier, PCOS variant, beauty variant, or longevity variant first
- Exit strategy framing — build to strategic acquisition Y3-Y5, or hold for cash-flow revenue